Search This Blog

Thursday, March 11, 2021

Pfizer vaccine 97% effective in preventing symptomatic Covid-19 disease: Study

 Pfizer-BioNTech's coronavirus vaccine has an efficacy of 97 per cent in preventing symptomatic disease, a study based on real-world evidence published on Thursday said. 

The study, conducted by the two pharma giants, also found that the vaccine's prevention against asymptomatic disease also stands at 94 per cent.

For the study, data from January 17 to March 6 from Israel's national vaccination campaign, has been taken. 

It also showed the vaccine is effective against a highly transmissible Covid-19 strain first found in the UK, known as B.1.1.7. Over 80 per cent of the specimens that were part of the study were of this variant. 

However, since only a few people in Israel have been infected with the South African variant B.1.351, the vaccine's efficacy against this strain could not be found. 

"This comprehensive real-world evidence ... can be of importance to countries around the world as they advance their own vaccination campaigns one year after the World Health Organization declared COVID-19 a pandemic," Pfizer and BioNTech said in a statement as quoted by news agency AFP.


Earlier, a similar study which was based on data from between December 20, 2020 and February 1, 2021 had shown the efficacy of 94 per cent in preventing symptomatic cases and 92 per cent in avoiding asymptomatic disease. 

https://www.wionews.com/science/pfizer-vaccine-97-effective-in-preventing-symptomatic-covid-19-disease-study-369728

Quest Diagnostics Updates Outlook for Investor Day

 - Company to repurchase $900 million of its shares in first half of 2021

- Long-term outlook 2022-24 compound annual growth rate (CAGR): Base business revenues (which excludes COVID-19 testing) expected to grow 4-5% and adjusted diluted earnings per share (EPS) for the total company expected to grow 7-9%

- Invigorate savings of 3% annually expected to continue

- COVID-19 testing is expected to continue into 2022 at lower levels as it moves from primarily clinical uses to testing in support of "Return-to-Life" activities

- Outlook for first half of 2021 remains unchanged

The Company's outlook for the first half of 2021 remains unchanged as follows:


Low


High


Net revenues

$4.85 billion


$5.15 billion


Net revenues increase

32.9%


41.1%


Reported diluted EPS

$5.07


$6.07


Adjusted diluted EPS

$5.90


$6.90


Cash provided by operations

At least $800 million


Capital expenditures

Approximately $200 million









The virtual event will begin at 9:00 am ET.  To access the live webcast, including audio, video and presentation slides, interested parties must register in advance here. Securities analysts and institutional investors are advised to register in advance.

Investors and analysts who register will have an opportunity to ask questions in live Q&A sessions with speakers. Participants who would like to ask a question can dial 888-455-0391 within the U.S. and Canada, or (773) 756-0467 internationally, using the passcode "7895081."

Interested parties unable to watch the live webcast will be able to view and listen to an archived copy of the webcast, which will be available on the Quest Diagnostics Investor Relations website following the conclusion of the event.  Anyone listening to the webcast is encouraged to read the company's periodic reports, on file with the Securities and Exchange Commission, including the discussion of risk factors and historical results of operations and financial condition in those reports.

https://www.prnewswire.com/news-releases/quest-diagnostics-updates-strategic-growth-drivers-and-provides-long-term-outlook-at-2021-virtual-investor-day-301245147.html

Rigel Completes Enrollment for NIH/NHLBI Phase 2 of Fostamatinib in COVID-19

 Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the completion of patient enrollment in a multi-center Phase 2 clinical trial to evaluate the safety of fostamatinib, Rigel's oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of hospitalized COVID-19 patients. The study is sponsored by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), in collaboration with Inova Health System. Fostamatinib is marketed in the U.S. as TAVALISSE® (fostamatinib disodium hexahydrate) tablets, and is approved in the U.S., Europe, and Canada as a treatment for adult chronic immune thrombocytopenia (ITP).

The Phase 2 clinical trial is being conducted at the NIH Clinical Center in Bethesda, Maryland, the nation's largest hospital devoted entirely to clinical research, and Inova Fairfax Hospital. 

This is a double-blind, placebo-controlled Phase 2 clinical trial that randomly assigned fostamatinib plus standard of care (SOC) or matched placebo plus SOC (1:1) to 58 evaluable patients who are a 5 to 7 on the 8-point ordinal scale (requiring supplemental oxygen via nasal canula or non-invasive ventilation, requiring mechanical ventilation or extracorporeal membrane oxygenation). Treatment will be administered orally twice daily for 14 days. There will be a follow-up period to day 60. The primary endpoint of this study is cumulative incidence of serious adverse events (SAE) through day 29, with multiple secondary endpoints designed to assess the early efficacy and clinically relevant endpoints of disease course as well as in vitro biological correlatives evaluating the effects of the drug on pathways involved in the pathophysiology of COVID-19, including NETosis. The NHLBI and Rigel expect to report topline data from this clinical trial in April 2021.

https://www.prnewswire.com/news-releases/rigel-announces-completion-of-patient-enrollment-for-nihnhlbi-sponsored-phase-2-trial-of-fostamatinib-in-hospitalized-covid-19-patients-301245219.html

Wednesday, March 10, 2021

75% of educators are vaccinated in Colorado

 Gov. Jared Polis is providing an update on the state's response to COVID-19.

Governor Polis had a call with the White House early today and Colorado will be getting 7,000 Johnson and Johnson and 10,000 more of Pfizer and Moderna next week.

Colorado vaccinated 75% of those educators kindergarten through grade 12; about 90% have received their first dose.

If you are 60 and older or are between the ages of 16 to 59 with two or more pre-existing conditions, you are now eligible as part of Phase 1B.3.

One in 236 Coloradans is currently infected with COVID-19.

It takes about two weeks after receiving your second dose -- or with Johnson and Johnson two weeks after your one dose -- to be considered fully vaccinated.

The CDC has said it is safe to be in a room where everyone has been fully vaccinated; you do not have to wear a mask. You do not have to have a quarantine period if you have been exposed to COVID-19 and you are fully vaccinated.

The governor also referenced the Boulder college party that occurred over the weekend, saying this behavior we cannot afford yet. He urges Coloradans to continue to wear a mask and social distance as more people are vaccinated.

Monday, a new COVID-variant was discovered in Colorado; there are currently three cases. This COVID-variant originated in South Africa known as B-1351. This variant does not seem to come from travel.

One of the people positive with this new variant is an inmate. Those that have been in contact with the inmate or work at the facility will be tested.

So far in the U.S., B-1351 has been identified in 20 different states.

This follows the first case of COVID-19 here in Colorado was confirmed one year ago Friday with the first case confirmed in El Paso County. As more and more Americans receive the COVID-19 vaccine, the CDC is expected to release new guidance about what kind of gatherings and social interactions are safe for fully vaccinated people.

With the upcoming weather conditions, Governor Polis says there are no vaccination clinics canceled yet. He urges people to keep their appointment, and you will be notified by the clinic if something changes.

https://www.koaa.com/news/covering-colorado/75-percent-of-educators-are-vaccinated-in-Colorado/

Spain to start opening tourism when vaccinated population hits 30-40%

 Spain, a country that depends heavily on tourism, has announced that it plans to reopen this spring and enjoy a more normal summer season.

This is due to its steady progression towards vaccinating its population. The specific goal is to start reopening for tourism once 30-40% of Spaniards have been vaccinated, Reyes Maroto, the country’s tourism minister, said.

According to El Español, an online newspaper in Spain, all Spaniards who are 45 years of age or older plus some younger than that age will be vaccinated by July.

Spain will receive 5 million doses from Pfizer in April, which will be added to doses from AstraZeneca, Jansen and Moderna. Up to now, 4.8 million doses have been administered in Spain with 1.4 million Spaniards having been fully vaccinated.

This country has been pushing for the European Union adopting health passports, which would indicate whether a traveler had been sick with the COVID-19 virus in the past, had taken a COVID-19 test and what the result of it was and whether or not they have been vaccinated against it.

Regardless of if the EU adopts a health passport, Spain is looking to introduce a vaccine passport within its country, Maroto said. “We want to be pioneers, and we are the most active champions of digital vaccine passports to facilitate international mobility.”

Tourists wearing face mask in Barcelona
Tourists wearing face mask in Barcelona, Credit – El Confidencial

The Balearic Islands, which is home to Mallorca, Menorca, Ibiza and Formentera Islands, would like to be the first to welcome visitors back via a vaccine passport pilot scheme. There is precedence for this as this region reopened to German tourists before the rest of Spain did so after a three-month lockdown period in 2020.Maroto also specifically mentioned British tourists, telling them to “keep open your expectations regarding holidays in Spain (this summer). We’re looking forward to welcoming you again.”

Currently, Spain’s borders are open to European Union and Schengen Area countries as well as to those from Australia, China, Japan, New Zealand, Rwanda, Singapore, South Korea, Thailand and Uruguay.

However, those from elsewhere will experience some restrictions or requirements or be outright banned from entering. For example, those from the United States may not enter unless they meet narrowly focused requirements; tourism is not one of them.

Those who may visit Spain must also ensure that they meet requirements put forth on the Spain Travel Health portal. Additionally, those from “risk” countries must provide a negative PCR test result from a test that had been taken within 72 hours of departing for Spain.

https://www.travelinglifestyle.net/spain-to-start-opening-tourism-when-reaches-30-40-of-vaccinated-population/


Texans 50 and older will be eligible for COVID vax starting March 15

 Texans age 50 and older will be eligible to receive the COVID-19 vaccine beginning March 15, state health officials announced Wednesday.

“Expanding to ages 50 to 64 will continue the state’s priorities of protecting those at the greatest risk of severe outcomes and preserving the state’s health care system,” said Imelda Garcia, Department of State Health Services associate commissioner for laboratory and infectious disease services and chair of the Expert Vaccine Allocation Panel.

The move to expand eligibility to a new category of Texans — labeled 1C — means that vaccine availability is ramping up across the state. However, appointments may continue to be hard to find, as the number of eligible recipients outnumbers the vaccine supply. Before the Wednesday announcement, between 10 million and 13 million people — more than one-third of Texas’ population — were already eligible, according to state health officials.

Previously, doses of the vaccine were limited to front-line health care workers, long-term care residents and staff, people 65 year old and older or at least 16 with a qualifying health condition. Last week, teachers and child care workers also became eligible, after President Joe Biden's administration directed states to prioritize school employees.

To date, nearly 7 million doses of the vaccine have been administered across Texas and more than 4.5 million people have received at least one dose, according to state data. In total, about 8.5% of the Texas population has been fully vaccinated.

In recent weeks, service workers, including grocery store and restaurant staff, have been advocating to be included in the next round of eligibility after spending nearly a year on the front lines of the pandemic.

Claudia Zapata, representative for the ATX Restaurant Organizing Project, said in a statement that she is “disappointed and angry but not surprised” that service workers were not given priority access to the vaccine.

The announcement comes on the same day that the statewide mask mandate ends, further stoking fear about the virus' spread among those in the industry. On Monday, service workers gathered outside the Texas Capitol to protest the decision to roll back safety restrictions and demand that they be given access to the vaccine.

Federal recommendations suggest all essential workers not included in phases 1A and 1B be included in this next phase, though Texas has previously strayed from that advice.

Texas is still far from herd immunity — the level at which a sufficient proportion of the population is immune to COVID-19 to stop its spread. Experts estimate that between 70% and 80% of Texans will need to be vaccinated to cross that threshold. That amounts to nearly 100% of adults in the state.

The announcement of the expanded vaccine eligibility comes on the same day that the statewide mask mandate ends. The mandate was first implemented by Gov. Greg Abbott last July. On Monday, service workers gathered outside the Texas Capitol to protest the decision to roll back safety restrictions and demand that they be given access to the vaccine.

Abbott hinted about the vaccine announcement during a press conference last week, when he announced he was rescinding the mask mandate and allowing every business —including restaurants, bars, retail stores and sports stadiums — to operate at 100% capacity. Abbott cited a number of key COVID-19 metrics, including a decline in new hospitalizations and the statewide positivity rate, as evidence that Texas is "in a far better position now."

In the nearly three months since Texas received its first shipments of the COVID-19 vaccine, supply has steadily increased. There are now three approved vaccines in the U.S. — Moderna and Pfizer-BioNTech, which both require two doses, and Johnson & Johnson, which requires one dose.

The Federal Emergency Management Agency and state emergency management officials have also begun running mass vaccination sites aimed at underserved communities in Houston and Dallas-Fort Worth. The sites are NRG Stadium in Houston, AT&T Stadium in Arlington and Fair Park in Dallas.

Concerns remain about equitable access to the vaccine. State Sen. Borris Miles, D-Houston, expressed frustration on Wednesday with the low vaccination rate among communities of color on which the pandemic has taken a disproportionate toll.

"I feel kind of that you broke my heart and broke your promise to me," Miles told Garcia, chair of the EVAP, during a state Senate Health and Human Services Committee meeting.

The increasing number of vaccinated Texans has meant, for some, a return to some semblance of normalcy. The U.S. Centers for Disease Control and Prevention on Monday announced that fully vaccinated people can visit safely with other vaccinated people and with small groups of unvaccinated people. But the CDC cautioned that COVID-19 still poses a grave public health risk, and urged everyone — including vaccinated people — to continue to wear masks and keep physical distance in public.

State health officials estimate that the vaccine will be available for the general public later this spring. Biden earlier this month said that the U.S. would have enough supply of the COVID-19 vaccine for every adult by the end of May.

Target to partner with CVS, distribute vaccine in stores in 17 states

 Target and CVS announced a partnership Wednesday that will allow CVS to administer the COVID-19 vaccine to people at CVS pharmacies located within Target stores.

This applies to more than 600 locations in 17 states, including South Carolina.

However, as of 10:41 a.m on Wednesday, the website shows all appointments in South Carolina are fully booked. The site states more appointments will open up as they become available and for customers to please check back later.

This vaccine will be for both Target and CVS customers as well as employees.

Target says it already supports CVS-administered vaccinations every year for the flu, as well as shingles and pneumonia. This is an extension of that partnership.

“We’ll continue to partner closely as they administer the vaccine while following state and federal guidelines. We’re also making fitting rooms available to CVS at select stores to host appointments,” Target said in a news release.

How to apply to get the vaccine at a CVS store inside Target

You’ll still need to go to CVS.com to check your eligibility and see if there’s a participating location near you.

You can also check out other places to sign up for the COVID-19 vaccine if those sign-up appointments are full.

Target plans to expand this partnership

“Target’s looking forward to providing even more support in the coming months,” it added. “That’ll mean continuing to work with CVS to offer vaccines to guests and team members within stores.”

It also plans to work on public vaccine education efforts, including the Health Action Alliance and the Ad Council’s new campaign. This campaign hopes to reach communities of color, which have been disproportionately effected by the pandemic and are getting the vaccine at lower rates.

https://www.wspa.com/news/top-stories/target-to-partner-with-cvs-distribute-vaccine-in-stores-in-17-states/